3WJ – targeting ligand-antiMIR17
Purpose:This nanoparticle can be used for specific delivery of anti-microRNA17 to cells in vitro and in vivo.
Get Quote| Product Name | Catalog number | Synthesis scale | |
|---|---|---|---|
|
Triple Negative Breast Cancer (TNBC)
|
3WJ – RFA (TNBC)-antiMIR17 | RNP-M17-01-1 |
1 nmol
|
| RNP-M17-01-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Triple Negative Breast Cancer ( TNBC) cells and antiMIR17] |
|||
| 3WJ – RFM-antiMIR17 | RNP-M17-07-1 | 1 nmol | |
| RNP-M17-07-2 | 50 nmol | ||
|
[Description: Serum stable 3WJ RNA nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR17] |
|||
| 3WJ – RFA(TNBC)-Scr | RNP-MSc-01-1 |
1 nmol
|
|
| RNP-MSc-01-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Triple Negative Breast Cancer (TNBC) cells and scramble miRNA.] |
|||
|
HER2+
Cancer
|
3WJ – RFA (HER2)-antiMIR17 | RNP-M17-03-1 |
1 nmol
|
| RNP-M17-03-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting HER2 + cancer cells and antiMIR17] |
|||
| 3WJ – RFM-antiMIR17 | RNP-M17-07-1 | 1 nmol | |
| RNP-M17-07-2 | 50 nmol | ||
|
[Description: Serum stable 3WJ RNA nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR17.] |
|||
| 3WJ – RFA(HER2)-Scr | RNP-MSc-03-1 |
1 nmol
|
|
| RNP-MSc-03-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting HER2 + cancer cells and scramble miRNA] |
|||
|
Folate Receptor+ Cancer
|
3WJ – RFC (FA)-antiMIR17 | RNP-M17-05-1 |
1 nmol
|
| RNP-M17-05-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with a folate ligand for targeting folate receptor (+) cells and antiMIR17] |
|||
| 3WJ – RF-antiMIR17 | RNP-M17-08-1 | 1 nmol | |
| RNP-M17-08-2 | 50 nmol | ||
|
[Description: Serum stable 3WJ RNA nanoparticle without ligand (serving as vector control) an but with antiMIR17] |
|||
| 3WJ – RFC(FA)-Scr | RNP-MSc-05-1 |
1 nmol
|
|
| RNP-MSc-05-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with a folate ligand for targeting folate receptor (+) cells and scramble miRNA] |
|||
|
Epithelial
Cancer
|
3WJ – RFA (EC)-antiMIR17 | RNP-M17-04-1 |
1 nmol
|
| RNP-M17-04-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Epithelial Cancer (EC) cells and antiMIR17] |
|||
| 3WJ – RFM-antiMIR17 | RNP-M17-07-1 | 1 nmol | |
| RNP-M17-07-2 | 50 nmol | ||
|
[Description: Serum stable 3WJ RNA nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR17] |
|||
| 3WJ – RFA(EC)-Scr | RNP-MSc-04-1 |
1 nmol
|
|
| RNP-MSc-04-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Epithelial Cancer (EC) cells and scramble miRNA] |
|||
|
Galactose Receptor+
Cancer
|
3WJ – RFC (GL)-antiMIR17 | RNP-M17-06-1 |
1 nmol
|
| RNP-M17-06-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with a galactose ligand for targeting liver cancer cells and antiMIR17] |
|||
| 3WJ – RF-antiMIR17 | RNP-M17-08-1 | 1 nmol | |
| RNP-M17-08-2 | 50 nmol | ||
|
[Description: Serum stable 3WJ RNA nanoparticle without ligand (serving as vector control) an but with antiMIR17] |
|||
| 3WJ – RFC(GL)-Scr | RNP-MSc-06-1 |
1 nmol
|
|
| RNP-MSc-06-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with a galactose ligand for targeting liver cancer cells and scramble miRNA] |
|||
|
PSMA+
Cancer
|
3WJ – RFA (PC)-antiMIR17 | RNP-M17-02-1 |
1 nmol
|
| RNP-M17-02-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Prostate Cancer (PC ) cells and antiMIR17] |
|||
| 3WJ – RFM-antiMIR17 | RNP-M17-07-1 | 1 nmol | |
| RNP-M17-07-2 | 50 nmol | ||
|
[Description: Serum stable 3WJ RNA nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR17] |
|||
| 3WJ – RFA(PC)-Scr | RNP-MSc-02-1 |
1 nmol
|
|
| RNP-MSc-02-2 |
50 nmol
|
||
|
[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Prostate Cancer (PC) cells and scramble miRNA] |
|||
